News

Tom Ryder Joins Focused Ultrasound Foundation Board of Directors

CHARLOTTESVILLE, VA – Thomas O. Ryder, an investor, entrepreneur, and retired corporate executive, was elected to the Focused Ultrasound Foundation’s Board of Directors at their March 1 meeting.

Ryder has served as Chairman and CEO of the Reader’s Digest Association and President of American Express’s Travel Related Services International, Merchant Services Worldwide, and American Express Publishing Worldwide divisions.

He has experience in the publishing industry, having worked at Time Inc., CBS, and Education Today Company, Inc. where he was co-founder and CEO.

Ryder has also served on numerous boards, including at Amazon for 20 years, during which time he was audit committee chairman and the first lead independent director.

Other previous board appointments have included Starwood Hotels, RPX Corporation, Startek Corp, American Express International Bank, and Virgin Mobile – where he was Chairman.

He is also a prolific writer on the subjects of food and wine.

“Tom brings his unsurpassed skills and experience to the Foundation’s leadership team,” said Foundation Chairman Neal F. Kassell, MD. “He will help to facilitate our efforts to overcome barriers and take advantage of opportunities to shorten the time for focused ultrasound to become a global standard of care.”

Ryder is also an essential tremor patient who underwent focused ultrasound therapy for the disorder in 2021.

“Focused ultrasound fixed a major problem I had with essential tremor and changed my life,” he explains. “I truly hope my tenure on the Foundation Board of Directors will give me the opportunity to share that miracle with others in similar need.”

Read more here.

Recent News

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast

10/10/2024

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near